BPC-157 vs TB-500 vs Combination Blend
Two distinct research peptides in the tissue research class — different origins, different characterized mechanisms — and the co-lyophilized blend for combination research protocols.
| Attribute | BPC-157 | TB-500 | Blend |
|---|---|---|---|
| Length | 15 amino acids | 7 amino acids (fragment) | Both, co-lyophilized |
| Parent protein | Human gastric protective protein | Thymosin beta-4 | — |
| Sequence | GEPPPGKPADDAGLV | LKKTETQ | — |
| Mechanism category | Signaling modulation (NO, growth factors) | Cytoskeletal / actin sequestering | Multi-pathway combined |
| Stability profile | Unusually stable; gastric pH survival in research | Standard peptide stability | Tested as a unit |
| HPLC purity | ≥99% | ≥99% | ≥99% (each component) |
| Per-lot COA | Yes | Yes | Single COA covers blend |
| Vial size | 10 mg | 10 mg | 20 mg total (10mg + 10mg) |
| Price | $53 | $64 | $129 |
What’s actually different
BPC-157 and TB-500 are often grouped together in research literature because they’re co-studied for tissue research applications. But they’re structurally and mechanistically distinct compounds.
BPC-157 — gastric protein fragment
BPC-157 is a 15-amino-acid synthetic peptide derived from a fragment of human gastric protective protein. The “BPC” name comes from “Body Protection Compound,” a label assigned by the original research group in the 1990s based on the fragment’s protective activity in animal model gastric studies.
Characterized mechanisms: modulation of nitric oxide synthesis, effects on growth factor expression (FGF, VEGF) in cell culture, modulation of dopaminergic and serotonergic systems in animal model neuroscience research.
Distinguishing feature: unusually stable for its size — survives gastric pH conditions in research models, which is uncommon for small peptides.
TB-500 — thymosin beta-4 fragment
TB-500 is a 7-amino-acid fragment (sequence: LKKTETQ) derived from the active domain of thymosin beta-4, a 43-amino-acid actin-sequestering protein found in most cell types. The full-length thymosin beta-4 was first isolated from thymus gland tissue in the 1980s.
Characterized mechanisms: actin sequestering (binds G-actin monomers, modulating cytoskeletal dynamics), cell migration effects in fibroblast/endothelial/stem cell assays, modulation of inflammatory mediators in cell culture.
Distinguishing feature: the fragment retains actin-binding activity of the parent protein but is much shorter and easier to synthesize, which is why TB-500 is more commercially accessible than full thymosin beta-4.
Why study them together (or as a blend)
BPC-157 acts on signaling pathways. TB-500 acts on cytoskeletal dynamics. Their characterized mechanisms are non-overlapping — which is precisely why they appear together in much of the published research literature on combination tissue protocols.
The BPC-157 / TB-500 Blend 20mg is supplied co-lyophilized — both compounds in a single vial, tested as a unit on a single COA. This simplifies combination research where the dose ratio is fixed (10mg BPC + 10mg TB).
QC notes specific to this class
BPC-157 and TB-500 are short peptides (15 and 7 residues respectively), well within the high-purity zone for solid-phase peptide synthesis. ≥99% purity is reliably achievable.
Blends require an additional QC step: confirming the ratio of compounds matches the labeled formulation. Matte’s blend COA reports the percentage of each component as analyzed in the final vial.
Storage and reconstitution
Same protocols apply across the class:
- Lyophilized: room-temp stable in transit; refrigerated for medium-term; frozen for long-term
- Reconstituted: refrigerated at 36–46°F, 30–60 day stability with bacteriostatic water
- Standard ratio: 2 mL BAC water per 10 mg → 5 mg/mL solution
Use the reconstitution calculator for the math on any vial size and target concentration.
Choosing for your protocol
- Single-mechanism studies → BPC-157 OR TB-500 standalone
- Combination research with fixed 1:1 ratio → BPC/TB Blend (simpler, one COA)
- Variable ratio research → standalone vials so you can dose independently
- Broader tissue research with copper peptide → consider the GLOW Blend (BPC + TB + GHK-Cu)
Detailed research background: Tissue Recovery Peptide Class Research Overview.